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Abstract. Increasing evidence is supporting the hypothesis of -synuclein pathology spreading from the gut to the brain
although the exact etiology of Parkinson’s disease (PD) is unknown. Furthermore, it has been proposed that inflammation,
via the gastrointestinal tract, potentially through infections, may contribute to -synuclein pathogenesis, and thus to the risk
of developing PD. Recently, many studies have shown that PD patients have an altered microbiota composition compared
to healthy controls. Inflammation in the gut might drive microbiota alterations or vice versa. Many studies focused on
the detection of biomarkers of the etiology, onset, or progression of PD however also report metabolites from bacterial
origin. These metabolites might reflect the bacterial composition and as well play an important role in immune homeostasis,
ultimately affecting the progression of PD. Besides the bacterial metabolites, pharmacological treatment of PD might play a
crucial role during the progression and thus treatment of the disease on the immune system. This review aims to establish a
link between the microbial composition with the observed alterations of bacterial metabolites and their impact on the immune
system, which could have influential effect in onset, progression and etiology of PD.
Keywords: Microbiota composition, bacterial metabolites, immune modulators, Parkinson’s disease, levodopa, dopamine
INTRODUCTION
Parkinson’s disease (PD) is the second-most occur-
ring neurodegenerative disorder worldwide [1]. The
prevalence of PD increases with age and peaks at 1.5
% between 85 years and 89 years of age and 6.1-6.2
million individuals were diagnosed with PD glob-
ally in 2015-2016 [1, 2]. The main feature observed
in PD patients is the aggregation of -synuclein in
Lewy bodies and loss of dopaminergic neurons in
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the substantia nigra pars compacta [3]. It has been
postulated that -synuclein pathology spreads out
from the enteric nervous system of the gastroin-
testinal tract to the central nervous system in the
brain [4]. Which is in agreement with the detec-
tion of -synuclein aggregates in colonic tissue and
appendix prior to the onset of PD [5, 6]. Recently, it
has been shown that pathogenic -synuclein aggre-
gates spread from the gut to the brain in a mouse
model, supporting Braak’s hypothesis of the etiol-
ogy of idiopathic PD [7]. Furthermore, increasing
evidence supports the involvement of the peripheral
immune system in PD. Inflammation via the gas-
trointestinal tract, potentially through infections, may
contribute to disease pathogenesis, and to the risk
of PD development, which was recently reviewed in
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[8, 9]. Houser and Tansey proposed a model of PD
pathogenesis originating from the gut where an ini-
tial inflammatory trigger could lead to a low-grade
inflammation, driving shifts in the microbiota compo-
sition, and increasing gut permeability, thus allowing
leakage of bacteria and their potential inflammatory
metabolites [8]. This leakage in gut barrier would
increase the blood-brain barrier permeability and -
synuclein pathology, which would ultimately lead to
neuroinflammation followed by neurodegeneration
[8]. Indeed, PD patients have an altered micro-
biota composition compared to healthy controls (HC)
[10–22], and one of the main bacterial metabolites,
short chain fatty acids (SCFA), have been implicated
in -synuclein pathology and microglia activation in
a mouse model of PD [23]. Altered microbial com-
position could lead to a shift in circulating bacterial
derived metabolites [24], and could be involved in
low-grade inflammation, an important trigger for the
onset of PD [8]. In this review, we aim to establish
a link between the microbial composition and the
reported alterations in their metabolic capacity that
have profound immune modulating properties, which
could potentially trigger onset, progression and eti-
ology of PD.
ALTERED BACTERIAL-DERIVED
METABOLITES IN PATIENTS WITH
PARKINSON’S DISEASE
Although it is clear that PD patients have an
altered microbiota composition [10–22], which was
reviewed recently [25, 26] and updated and merged
in Table 1, there is a large variation among studies
and there is no clear consensus about which bacteria
might be involved, which might be due to several
factors including sample storage, technical differ-
ences of sampling, sequencing methods, statistical
approach, demographics, clinical details, and sam-
ple size [10]. Nevertheless, the altered microbiota
composition could result in metabolic changes in PD
patients which could play an important role in dis-
ease onset and progression of PD [24]. Therefore,
many studies focused on metabolic biomarker screen-
ing (comparing healthy subjects with either familial
PD or idiopathic PD), for an early detection of poten-
tial development of PD. The metabolic profiles of
PD patients (in cerebrospinal fluid (CSF), blood or
urine) usually reflect oxidative stress [24, 27–31]
or mitochondrial dysfunction [24, 31–35]. However,
many studies also observed differences in metabo-
lites from bacterial origin, which are summarized in
Table 2.
Comparing the 13 different studies in Table 1, 62%
(8/13) report a decrease in species from the Lach-
nospiraceae family (including Blautia sp., Dorea
sp., Coprococcus sp., Rosburia sp., and Clostridium
XIVa sp.), 38% (5/13) report a decrease of Faecal-
ibacterium sp., and 15% (2/13) report a decrease in
Bacteroides sp. (one study reported an increase), all
of which are known to be SCFAs producers [36].
In mouse models, it was shown that the gut
microbiota is involved in -synuclein aggregation
pathology through their production of SCFAs [23].
Using murine models overexpressing -synuclein,
germ-free (GF) or antibiotic treated mice had
reduced PD pathology compared to conventional
mice. In addition, when those GF or antibiotic treated
mice were administered a mixture of SCFAs, the
PD pathology was restored as observed in their
conventional counterparts [23]. GF mice (WT or
overexpressing -synuclein) colonized with human
stool from PD patients had increased relative lev-
els of butyrate and propionate but decreased levels
of acetate compared to mice colonized with human
stool from HCs [23]. These findings are in contrast
with the finding that PD patients have decreased lev-
els of absolute SCFAs and reduced relative levels
of butyrate but not acetate and propionate in their
stool samples compared to age matched HCs [14],
which is in agreement with reduced levels of acetate
found in the blood of PD patients [37]. This dis-
crepancy is most likely because of the differences
between humans and mice, specifically those born
germ-free. In addition, in Sampson et al. (2016) [23]
mice were recolonized with human faecal transplant,
representing more acute effects as well as shifts in the
microbiome based on species effects.
A decrease in Prevotellaceae or Prevotella sp.
was observed in 31% (4/13) of the studies listed in
Table 1. Prevotella produces (among others) hydro-
gen sulfide (H2S), a gasotransmitter (for review see
[38]), which has been linked to PD and neuropro-
tection [39]. Free H2S levels in plasma, cecum,
and colon of germ-free mice were significantly
reduced compared to their conventional counterparts,
indicating that the microbiota contributes to free
H2S levels [40]. H2S breathing (40 ppm) restored
the movement disorder, protected dopaminergic
neurons, prevented microglia and astrocyte activa-
tion and upregulated the expression of antioxidant




















Bacterial composition alterations in PD patients compared to healthy controls







16S rRNA 64 64 Feces [10]
Lachnospiraceae Akkermansia muciniphila,
Enterobacteriaceae, Lactobacillaceae
16S rRNA 193 113 Feces [11]




31 28 Feces [15]
Clostridium coccoides, Clostridium leptum,
Bacteroides fragilis, Prevotella (ns)
Lactobacillus sp. Targeted qPCR for 19
species





16S rRNA 212 136 Feces [17]
none Lactobacillaceae, Barnesiellaceae,
Enterococcaceae
16S rRNA 29 29 Feces [18]
Corpobacillaceae, Lachnospiraceae
(Blautia sp., Dorea sp., Roseburia sp.,
Coprococcus sp.)
Bacteroides sp. 16S rRNA 38 34 Feces [19]
Coprobacillaceae, Lachnospiraceae (Dorea
sp.), Faecalibacterium sp.
Oxalobacteraceae, Ralstonia 16S rRNA 38 34 Sigmoid mucosa [19]
Blautia sp., Faecalibacterium sp.,
Ruminococcus sp.
Escherichia sp., Streptococcus sp., Proteus
sp., Enterococcus sp.
16S rRNA 24 14 Feces [20]
Lachnospiraceae Eubacteraceae, Biﬁdobacteraceae 16S rRNA 75 45 Feces [21]
Dorea sp., Bacteroides sp., Prevotella sp.,
Faecalibacterium sp.
Lactobacillus sp., Christensenella sp.,
Catabacter sp., Oscillospira sp.,
Biﬁdobacterium sp.
16S rRNA 89 66 Feces [22]





16S rRNA 72 72 Feces [12]
Lactobacillus, Sediminibacterium Clostridium IV, Aquabacterium,
Holdemania, Sphingomonas, Clostridium
XVIII, Butyricicoccus, Anaerotruncus




Enterobacteriaceae, Biﬁdobacterium sp. Targeted qPCR for 9
taxa
34 34 Feces [14]



















Bacterial metabolites significantly altered in PD patients compared to healthy controls
Study Sample PD Healthy Method Decreased (FC, PD vs HC) Increased (FC, PD vs HC) Description
[29] CSF 34 35 GC-MS none none Lumbar puncture after fasting.
[31] CSF 31 95 FT-ICR-MS none p-cresol sulfate (9.29); quinic acid (1.7) Lumbar puncture; 18 patients without PD
medications and 11 with PD medication.
[90] CSF 48 57 GC/LC-MS none none Postmortem (within 4 hours) collection of
lateral ventricular CSF.
[91] CSF 10 10 1D 1H-NMR none none Six patients started dopaminergic treatment
at the time of CSF collection.
[55] CSF, Plasma 20 20 GC-TOF-MS none none PD baseline; Samples were collected without
overnight fasting, between 8-9 AM.
[48] CSF, Plasma 49∗ NA LC-GC-MS Correlation with the progression of PD:
Benzoic acid (CSF: r = –0.42, plasma: ns)
Correlation with the progression of PD:
indoleacetic acid (CSF:0.29, plasma: ns)
∗Placebo treated PD patients from study
from 1989. Lumbar puncture for CSF
samples and blood samples were collected
after overnight bed rest (between 6 and 10
AM before breakfast).
[92] CSF, Plasma 22 28 GC/LC-MS 3-(4-hydroxyphenyl)acetic acid (NA) indole (NA) Lumbar puncture and plasma samples from
non-fasting patients; Samples were age,
sex, and sampling-date matched.
[93] CSF, Plasma 26 14 LC-MS none none Lumbar punctures were performed between
09.30 and 10.00 am after overnight fasting;
Blood was drawn from the cubital fossa
immediately after the lumbar puncture.
[37] Plasma 43 37 2D 1H-NMR trimethylamine (NA), acetate (NA),
threonate (NA)
none Samples were obtained from drug-naı¨ve PD
patients with age and gender-matched
healthy controls.
[94] Plasma 53 46 LC-ECA none none 53 PD patients (41 iPD, 12 LRRK2G2019S)
were compared to 31 healthy family
members (21 positive and 10 negative for
LRRK2 mutation) and 15 non-related
controls.
[28] Serum 35 7 GC/LC-MS indoleacetic acid (0.67) phenyllactate (1.84);
3-(4-hydroxyphenyl)lactate (1.23)
Blood was withdrawn after 4 hours of
fasting.
[33] Serum 41 40 DiscoveryHD4TM
Metabolon
Platform
catechol sulfate (0.62) none Mass spectrometry-based; Blood was
withdrawn after fasting from 41 idiopathic



















[30] Serum 43 42 CIT-LC-MS none vanillic acid (3.48) (mainly dietary source) Determined of PD patients not developing
dementia (n = 27) and PD patients that did
develop dementia (n = 16). Blood was
withdrawn at baseline.
[32] Serum 28 18 LC-MS none none Blood was withdrawn in the morning before
any food or drink.
[24] Serum 6 19 LC-MS indoleacetic acid (0.82); hippuric acid





none PARK2 PD patients; Blood was withdrawn
after overnight fasting.
[68] Serum 48# 10 LC-MS phenylethylamine (0.34d, 0.16e) tyramine (1.70d, 2.44e) #21 de novo PD patients, dde novo PD
patients, etreated PD patients; Blood was
withdrawn in the morning after fasting.
[95] Serum 80 20 LC-FT-ICR-MS none none 39 rapid progressing PD Patients and 41
slowly progressing PD patients. No fasting
was required. No medication was allowed
in the morning. Samples were taken at the
morning exam between 8 AM and 12 PM
[35] Urine 106 104 LC-MS none 3-(4-hydroxyphenyl)acetic acid (1.96–2.16);
tryptamine (2.22–3.31); indoleacetic acid
(1.66–3.23); phenylacetic acid (2.36–2.71)
After overnight fasting morning midstream
urine samples were collected at week 0, 16
and 32.
[34] Urine 92 65 GC/LC-MS none 3-(4-hydroxyphenyl)acetic acid (1.66a,
2.78b, 5.85c); indoleacetic acid (2.64a,
3.49b, 1.88c); aminobenzoic acid (6.63a,
25.43b, 16.74c); hydroxybenzoic acid
(4.30a, 4.26b, 6.68c)
After overnight fasting morning midstream
urine samples were collected at week 0, 16
and 32; aEarly-stage (HY 1–1.5),
bMid-stage (HY 2–2.5), cAdvanced-stage
(HY 3-4).
[14] Feces 34 44$ GC-MS acetate (0.43f , 0.71g), butyrate (0.38f ,
0.57g), propionate (0.48f , 0.61g)
none $34 age matched controls and 10 young
healthy controls. Fold changes derived
from figure compared to young controlsg
and age matched controlsf . All subjects
were on an omnivorous diet without
special dietary habits or restrictions.
During the last 3 months no intake of
antibiotics, probiotics, or prebiotics was
reported.
∗Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989;321:1364–1371. GC, gas chromatography; LC, liquid chromatography,
MS, mass spectrometry; CIT, chemical isotope labeling; FT-ICR, Fourier-transform ion cyclotron resonance; NMR, nuclear magnetic resonance; LC-ECA, LC, electrochemical Array.
S364 S.P. van Kessel and S. El Aidy / Altered Metabolites in Parkinson’s Disease
PD mouse model [41]. Similar results were found
in a 6-hydroxydopamine (6-OHDA) and rotenone
induced PD rat model receiving 30 or 100mol/kg
NaHS (an H2S donor) [42]. Similarly, H2 another
and potentially overlooked gasotransmitter, which
can be produced by gut microbiota, such as Blautia
sp. Clostridium spp., might have an important link
to PD as it has been described to neutralize toxic
hydroxyl radicals, downregulate the expression of
proinflammatory factors, and preserve cerebrovas-
cular reactivity [43]. Intriguingly, 0.08 ppm of H2
in drinking water reduced the loss dopaminergic
neurons by 16% compared to the control in the sub-
stantia nigra and slightly improved the mobility in
an open-field test using a MPTP induced PD mouse
model [44]. Similarly, the protection of dopaminer-
gic neurons, by drinking hydrogenated water, was
also observed in a 6-OHDA rat model [45]. Bacterial
species representing the genera of bacteria altered in
PD have been tested for their production of H2 [46].
Blautia coccoides and Clostridium leptum, which
are reported to be underrepresented in PD patients
(Table 1) produced the highest levels of H2 (∼1.6
and 0.62mol/108 cells) [46], and therefore might
contribute to the availability of molecular H2 which
potentially plays a role in neuroprotection.
Other organic metabolites produced by Clostrid-
ium species [47] were found to be differentially
present in serum, urine, and CSF samples of PD
patients (Table 2). For example, an increase in 3-
phenyllactate, and 3-(4-hydroxyphenyl)lactic acid
and a decrease of indoleacetic acid (IAA) was
observed in serum of patients with idiopathic PD and
familial PD (PARK2 mutations) [24, 28], although
in urine, an increase of 3-(4-hydroxyphenyl)acetic
acid and IAA was observed [34, 35]. In addition,
a minor but significant correlation was observed
between IAA and the progression of PD in CSF but
not in plasma, however these samples were stored
for 25 years before analysis on LC/GC-MS, which
could influence the accuracy of sample analysis
[48]. IAA is produced via oxidative decarboxyla-
tion or deamination of indolepyruvate or tryptamine,
respectively. Levels of IAA and tryptamine, pro-
duced by Ruminococcus gnavus and Clostridium
sporogenes [49], are strongly dependent on the micro-
biota as GF mice showed ∼30 fold decrease in
IAA cecal or fecal levels and a corresponding ∼10
fold decrease in tryptamine levels when compared
to their conventional raised counterparts [50, 51].
Congruously to the increased IAA levels in urine,
an increase in tryptamine was detected in urine
of PD patients in one of the studies [35]. Impor-
tantly, IAA was shown to modulate inflammatory
responses reducing pro-inflammatory cytokine pro-
duction by macrophages stimulated with LPS and
palmitate or attenuating the cytokine mediated lipo-
genesis through the aryl hydrogen receptor (AHR)
in hepatocytes [51]. Furthermore, IAA has an anti-
neuroinflammatory activity in LPS-stimulated BV2
microglial cells [52]. Taken together, data available
suggest that altered levels of IAA, which are caused
by changes in microbial composition, might play a
role in attenuating inflammation in PD patients.
p-Cresol sulfate (sulfonated by the liver), which
is exclusively produced by gut bacteria [53], mainly
by species belonging to Clostridiaceae (Clostridium
clusters I, IV, IX, XI, XIII, XIVa, XVI) and Bac-
teroidaceae families [54] (Table 1), is also observed
to be ∼10 fold increased in in the CSF of PD patients
[31] but not in blood samples [24, 28]. However, dif-
ferential metabolite levels in blood do not necessarily
reflect CSF levels [55]. p-Cresol has a profound effect
on the inflammatory response of macrophages and
T-cells [56–58]. In murine peritoneal exudate cells
(the adherent fraction, mainly macrophages) and in
a J774.1 macrophage cell line, pre-treatment with p-
cresol at non-cytotoxic levels was able to inhibit Il-12
production after stimulation with heat-killed Lacto-
bacillis casei [56]. The same effect was observed later
in murine peritoneal exudate cells and RAW276.3
macrophage cell-line stimulated with LPS or LPS
and IFN [58]. In addition, p-cresol sulfate increased
Il-10 levels but did not alter levels of TNFa [58].
In a hypersensitive mouse model, p-cresol and p-
cresol sulfate correlated negatively with ear swelling,
suggesting that p-cresol (sulfate) attenuates T cell
mediated immune response [57]. When in vitroCD3+
splenocytes were stimulated with p-cresol or p-cresol
sulfate a decrease in IFN and an increase IL-4 levels
were observed, which was confirmed by a decreased
Th1/Th2 ratio (CD3+/CD4+ splenocytes, intracellu-
lar stained for IFN (Th1) or IL-4 (Th2) production),
but no difference between untreated and p-cresol
treated cytotoxic T-cells or regulatory T-cells were
found [57].
In contrast to p-cresol sulfate, catechol sulfate,
a product of bacterial and human co-metabolism,
was found to be decreased in PD patients [24, 33].
Catechol is an intermediate bacterial product from
the benzoate degradation pathway [59, 60]. Notably,
higher bacterial metabolism of catechol seems to be
associated with inflammation as concluded from the
higher relative abundance of bacteria representing
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the benzoate pathway are higher in a murine colitis
model during the active disease compared to remis-
sion [60]. For example, Ralstonia pickettii, which is
known to produce and degrade catechol [61, 62] was
reported to be increased in the sigmoid mucosa of
PD patients (Table 1) potentially reflecting inflam-
mation [19], which is in agreement with the reported
higher abundance of bacteria representing the ben-
zoate degradation pathway [60].
Molecular mimicry by extracellular amyloid pro-
teins produced by bacteria have been proposed as
one potential trigger inducing misfolding of neuronal
proteins via cross-seeding [63]. Recently the amy-
loid protein produced by Escherichia coli (curli) has
been implicated in -synuclein pathology in rats and
Caenorhabditis elegans [64]. Rats orally adminis-
tered with wild type E. coli or E. coli lacking the
curli-gene revealed increased-synuclein aggregates
in the brain and gut of rats (hippocampus, stria-
tum, and enteric nervous system) when treated with
wild type E. coli. Furthermore, increased expres-
sion of IL-6, TLR2 and TNF were observed in
the striatum or rats treated with wild type E. coli
[64]. Various species from the Enterobacteriaceae
family (E. coli, Salmonella typhimurium Citrobac-
ter sp., Citrobacter freundii, Cronobacter sakazakii,
and Proteus mirabilis) produce curli [65]. Impor-
tantly, 31% (4/13) of the studies reported increased
abundance of Enterobacteriaceae spp. [11, 12, 14,
20] (Table 1). Intriguingly, oral administration of
P. mirabilis in a MPTP induced PD mouse model
induced neuronal damage, motor deficits, neuroin-
flammation and -synuclein aggregation [66]. The
authors suggested that higher levels of LPS by P.
mirabilis induced the observed neuronal damage.
However, the fact that P. mirabilis produces curli
could be another factor involved in the observed PD
pathology.
BACTERIAL-MEDIATED SIDE EFFECTS
OF PARKINSON’S DISEASE TREATMENT
Orally administered PD medication could have an
effect on gastrointestinal (GI) function and there-
fore on the microbial composition alterations in
PD patients. For example, the COMT-inhibitors,
anticholinergics and levodopa/carbidiopa (border-
line significant) were associated with microbiota
alterations within PD patients [17]. Furthermore,
COMT-inhibitors were significantly associated with
an increase of Lactobacillaceae and a decrease of
Clostridiales Family IV (Incertae Sedis) [12]. In 54%
(7/13) of the studies Lactobacillaceae or Lactobacil-
lus were reported to be increased in PD patients
(Table 1). Some Lactobacillus species are known
to produce tyramine [67] and tyramine has been
proposed as a biomarker for PD patients because
of the significantly higher levels of tyramine com-
pared to HC observed in the blood circulation (2.4
and 1.7 fold, respectively) [68], Table 2. Although
other studies did not find an increase in tyramine, an
increase in the downstream metabolite of tyramine,
3-(4-hydroxyphenyl) acetic acid, was observed in PD
patients [34, 35], potentially supporting increased
levels of tyramine. The authors associated the human
aromatic amino acid decarboxylase (AADC, also
known as DOPA decarboxylase (DDC)) with the
observed levels, without speculating about possible
contribution of gut bacteria. Tyramine is abundant in
fermented foods particularly produced by lactic acid
bacteria (Lactobacillus sp., Enterococcus sp.) harbor-
ing tyrosine decarboxylases (TDC), which are also
commensals in the human GI-tract [67, 69, 70]. Tyra-
mine is produced in the small intestinal content of rat,
indicating that small intestinal bacteria contribute to
tyramine levels in vivo. In addition, tdc-gene abun-
dance correlated positively (r = 0.82, n = 10) with the
disease duration of PD [71], supporting the increased
abundance of Lactobacillaceae or Lactobacillus
found in PD patients. Besides the decarboxylation of
tyrosine to tyramine, the study also showed that bac-
teria harboring TDC can effectively decarboxylate
levodopa to dopamine, and might compromise the
levels of levodopa in the gut, before it can reach the
brain [71], which was later independently confirmed
in human stool samples and using a TDC inhibitor in
mice colonized with E. faecalis [72]. Co-prescribed
decarboxylase inhibiters, mainly carbidopa, prevent
peripheral decarboxylation of levodopa treatment by
the human AADC (DDC), which however do not
affect the bacterial TDCs [71]. The inadequate block-
ing of bacterial TDC might result in higher levels
of luminal dopamine produced by the gut bacte-
ria (65). Thus, because of levodopa treatment, PD
patients are exposed to higher circulating levels of
dopamine compared to matched HCs. Indeed, serum
dopamine levels (sulfonated by the liver) are found
to be 30–40 times higher compared to HC [24] and
serum dopamine levels correlated with the dosage
of levodopa [73]. Comparing healthy and PD sub-
jects on either a low dose (400 mg/day) or a on
a high dose (700 mg/day) of levodopa showed that
PD patients on a high dosage of levodopa have
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significantly more dopamine in their peripheral blood
lymphocytes (PBLs), however, (nor)epinephrine or
DOPAC levels were not altered [74]. In contrast, non-
treated PD patients have low dopamine levels in their
PBLs, even ∼3 fold lower than in healthy subjects,
but after treatment showed an ∼30 fold increase in
the PBL dopamine content [75]. Likewise, higher lev-
els of dopamine were detected in plasma of levodopa
treated PD patients (∼2.5 fold increase) compared to
HC or de novo PD patients and no significant differ-
ences were observed between HC and de novo PD
patients [76].
The high levels of dopamine exposure in PD
patients, resulting from bacterial and human levodopa
metabolism, could affect immune homeostasis, as
dopaminergic systems are involved in either the adap-
tive and innate immune system, recently reviewed
[77, 78]. Dopamine receptors are widely expressed on
human leukocytes and dopamine, through its recep-
tors, can modulate T-cell response, and might act as
auto- or paracrine signaling molecule in the cells
of the immune system [78]. Importantly, the per-
centage of Dopamine Receptor D5 (DRD5) positive
CD4+ T-cells correlated negatively with the UPDRS-
III (Unified Parkinson’s Disease Rating Scale, Part
III, motor examination) score [76], indicating that
the severity (progression) of the disease, and thus
the disease duration [79] and drug treatment might
be associated with reduced DRD5+ CD4+ T-cells.
A follow up study investigating CD4+ T cell sub-
sets (T helper cells, TH1, TH2, TH17; and T regulatory
cells, Treg) showed an overall decrease of CD4+ T
cells in de novo PD patients and treated PD patients
attributed by a decrease in most T-cell subsets except
for TH1. Remarkably, there were little differences
observed between the de novo PD and treated PD
patients except for Treg mediated inhibition of T
effector cell (Teff , mixture of T helper cells) pro-
liferation by dopamine. Treg subsets from healthy
subjects, de novo PD patients, and treated PD patients
showed similar Treg mediated inhibition of Teff pro-
liferation, which is almost abolished by dopamine
except for Treg cells isolated from treated PD patients,
those cells appeared to be insensitive to dopamine
[80]. This finding is consistent with an earlier report
showing that dopamine prevents inhibition of murine
Teff proliferation by Treg cells [81]. Furthermore, it
was shown that the effect of dopamine was mediated
through DRD1-like receptors (DRD1 or DRD5) [81],
which is in agreement with the negative correlation
observed between disease severity (and thus indi-
rectly disease and treatment duration) and DRD5+
CD4+ T-cells in PD patients [76]. This Treg insen-
sitivity might potentially be originated from the
long-term levodopa treatment of PD patients. In addi-
tion, DRD2-like receptors (D2, D3, D4) seem to be
involved in the dopaminergic immune pathway in
PD. DRD3 knock out (KO) mice or RAG1 KO mice
(which are devoid of T and B cells) reconstituted
with DRD3-deficient splenocytes or DRD3-deficient
CD4+ T cells resulted in a strong neuroprotection in
MPTP-induced PD, showing a fundamental role of
DRD3 expressed on CD4+ T cells in the degener-
ation of dopaminergic neurons. Furthermore it was
shown that DRD3 deficient CD4+ T cells are unable
to acquire the Th1 effector phenotype, indicating that
dopaminergic signaling (by dopamine or agonists)
through DRD3 would produce Th1 cells which are
key in neurodegeneration observed [82]. Which is in
agreement with the higher Th1/Th2 ratio observed
in progressing PD patients but not in de novo PD
patients, potentially through dopamine mediated Th1
differentiation in combination with the inability of
Treg cells to inhibit Teff cells [80].
Besides levodopa, which results in higher exposer
to peripheral dopamine, blocking DDC to avoid
peripheral conversion of levodopa to dopamine,
might have a profound influence on the immune sys-
tem. Recently, it has been reported that carbidopa, a
DDC inhibitor, has immunosuppressive properties as
it prevents T-cell proliferation and T-cell autoimmu-
nity in a mouse model [83]. Furthermore, it has been
demonstrated that carbidopa is an AHR-ligand [84],
and therefore might play a role in the immune system,
as AHR is an important contributor to the adaptive
immune system by modulating T-cell differentiation,
reviewed recently [85].
Importantly, proliferation of murine B-cell
enriched lymphocyte cultures isolated from spleen,
lymph nodes and Peyer’s patches are inhibited by
dopamine in a concentration dependent manner
(1–100M), which coincided with immunoglobulin
production (IgA, IgM, IgG) [86]. IgA is known to
shape the microbiota composition, reviewed here
[87], and thus a decrease in IgA production due to
the exposure to dopamine could potentially lead to
alteration in the microbiota composition. In a recent
study, inflammatory markers in fecal samples of PD
patients were compared to their HCs counterparts.
The mean levels of the angiogenesis factor (Flt1),
the pro-inflammatory cytokines IL-1, and CXCL8
were significantly higher in PD patients. Impor-
tantly, consumption of probiotics was associated
with significantly higher levels of the chemokines
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CCL4 (MIP-1), and CCL17 (TARC), and the
pro-inflammatory cytokine IL-7 [88]. Unfortunately,
the potential effect of anti-Parkinson medication on
the fecal immune profiles was not included in the
analysis, which could have a profound effect on the
outcome (discussed above).
CONCLUSION
Microbial dysbiosis might be a contributing fac-
tor to the onset and/or progression and severity of
PD. Altered bacterial composition might result in
a change in bacterial metabolites as detected in
PD patients, contributing to the immune homeosta-
sis, and potentially detrimental for the onset and
progression of the disease. Equally important is
the pharmacological treatment of PD, which might
further contribute to a disturbed immune system.
Nonetheless, it remains to be elucidated what drives
the modulation of the microbial composition in PD
patients. Many studies have focused on the metabolic
profile of PD patients in CSF, blood, or urine in
order to find potential biomarkers for the etiology,
onset, or progression of the disease. Many of these
altered metabolites are bacterial products, reflect-
ing a deviation in the microbial composition of
PD patients, and therefore might act as an impor-
tant biomarker for microbial dysbiosis. In addition,
those bacterial-derived metabolites show impor-
tant immunomodulatory properties, which might be
important for the progression of the disease.
The main metabolites found have phenol/indole
moieties and are mainly produced by bacteria from
the Clostrida class, which are also known SCFAs
producers. Notably, alterations in SCFAs were not
reported in the majority of metabolomics studies,
most likely because of the methods used for the
untargeted metabolomics. Because SCFAs have a
potential effect on the -synuclein pathology, tar-
geted metabolomics for SCFAs should be performed
in future metabolomics studies, as they might give
clues about abnormal levels in PD patients poten-
tially influencing PD pathology. Furthermore, altered
levels of SCFAs could be linked with the levels of
p-cresol and IAA as these metabolites are produced
mainly by Clostridia [47, 54], the main butyrate pro-
ducing bacteria in the gut [89]. Taken together, further
research on the metabolites produced by the gut
microbiota is necessary to unravel the complex inter-
action of multiple facets of metabolites originating
from altered microbial composition and pharma-
cological treatment on the immune system in PD
patients to give further insights on the role of gut
microbiota and their metabolites on the onset, pro-
gression and etiology of the disease. Standardized
methods of stool sampling and sequencing technol-
ogy should be developed to generate more consensus
among metabolomic and microbiota studies. Addi-
tionally studies should be conducted with focus on
determining the fecal metabolome from PD patients
in context of the pathology and progression of the
disease. Diet as well as medication are confound-
ing factors that influence changes in the microbiota,
thus should be taken into consideration in the data
analyses.
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